EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
Affimed tries to convince with seven patients
Luminice-203 yields its first topline data, but where are all the patients?
FDA green and red lights: May 2024
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
Revolution sees a new pan-KRAS challenger
Pfizer moves to take PF-07934040 into its first clinical trial.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
Replimune challenges Iovance
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Telix heads to the US, as RayzeBio runs into problems
Supply continues to cause headaches for radiopharmaceutical developers.
